New research published in the Journal of the Peripheral Nervous System (Sloan et al., 2026) shows that the understanding of peripheral nerve damage caused by diabetes (DPN) is shifting. DPN has long been regarded as irreversible, but a growing number of studies suggest that nerve damage can be reversed, especially if the condition is detected early.
The current publication provides a review of research both supporting and opposing the possibility of reversing diabetes-related nerve damage. The researchers’ key message in favour of reversibility is that it depends on timing. Early nerve dysfunction is functional and potentially modifiable. Once structural damage has been established, the possibilities are limited. Lifestyle changes and new treatment approaches have in several studies produced measurable improvements in nerve function.
This represents a shift in consensus that opens up new opportunities, both for patients and for the clinicians working in diabetes care. The researchers explicitly highlight the need for standardised measurement methods for early nerve dysfunction as a priority for future research and clinical practice.
The arguments against the reversibility of nerve damage are largely based on the fact that the damage is caused by impaired microcirculation. Since it has not been clinically demonstrated that such a condition can be improved, this serves as an indirect argument against the reversibility of nerve damage. Another argument against is that it is difficult to measure nerve function using available methods.
“This is a very interesting publication where both the arguments for and against support our instrument VibroSense Meter II as an objective and reliable tool for assessing nerve function. Other existing methods are far too coarse, which in turn means that small changes cannot be detected”, says Toni Speidel, CEO of VibroSense Dynamics AB.
Read the full article at Sloan G et al. Journal of the Peripheral Nervous System, 2026; 31:e70124. doi: 10.1111/jns.70124
For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ)
Tel: +46 40 88 026
E-mail: info@vibrosense.se
www.vibrosense.se
“The new Gold Standard for reliable
detection of nerve damage”
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical device products and services for diagnostic support in the assessment of nerve damage in hands and feet. The method involves measuring and quantifying the ability to perceive vibrations at multiple frequencies applied to the skin. The company’s customers include diabetes clinics, occupational health services, hospitals, primary care centres, and researchers.
Our vision is for the company’s products to become a standard instrument in all neurological examinations, in order to detect early signs of changes in sensation so that patients and their healthcare providers can implement preventive measures that prevent, reduce, or delay the onset of nerve damage in the hands and feet.